ArticleBiomedicines2021
Development of Vancomycin Delivery Systems Based on Autologous 3D Platelet-Rich Fibrin Matrices for Bone Tissue Engineering.
Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Intrawound vancomycin powder for prevention of surgical site infections in primary joint arthroplasty: an umbrella review of systematic reviews and meta-analyses.International journal of surgery (London, England) · 2025Pooled it
- Antibiotic-Loaded Platelet-Rich Fibrin (AL-PRF) as a New Carrier for Antimicrobials: A Systematic Review of In Vitro Studies.International journal of molecular sciences · 2025Pooled it
- Application of Platelet-Rich Fibrin and Concentrated Growth Factors as Carriers for Antifungal Drugs-In Vitro Study.Journal of clinical medicine · 2025Article
- Comparative Evaluation of Platelet-Rich Fibrin (PRF) and Concentrated Growth Factor (CGF) as Carriers for Antibiotics-In Vitro Study.International journal of molecular sciences · 2025Article
- How to explain the beneficial effects of leukocyte- and platelet-rich fibrin.Periodontology 2000 · 2025Review
- The Role of Autologous Platelet Concentrates as a Local Antibiotic Delivery System: A Systematic Scoping Review.Antibiotics (Basel, Switzerland) · 2024Article
- Platelet-rich fibrin as an autologous biomaterial for bone regeneration: mechanisms, applications, optimization.Frontiers in bioengineering and biotechnology · 2024Review
- Recent advances in nanostructured delivery systems for vancomycin.Nanomedicine (London, England) · 2024Review
- Fibrin-Rhamnogalacturonan I Composite Gel for Therapeutic Enzyme Delivery to Intestinal Tumors.International journal of molecular sciences · 2023Article
- Research Progress of Design Drugs and Composite Biomaterials in Bone Tissue Engineering.International journal of nanomedicine · 2023Review
- Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam.Clinical oral investigations · 2022Article
- Gradual Drug Release Membranes and Films Used for the Treatment of Periodontal Disease.Membranes · 2022Review
- Emerging Bioactive Agent Delivery-Based Regenerative Therapies for Lower Genitourinary Tissues.Pharmaceutics · 2022Review
- Advances in Fibrin-Based Materials in Wound Repair: A Review.Molecules (Basel, Switzerland) · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Autologous platelet-rich fibrin (PRF) is derived from the blood and its use in the bone tissue engineering has emerged as an effective strategy for novel drug and growth factor delivery systems. Studies have approved that combined therapy with PRF ensures higher biological outcomes, but patients still undergo additional treatment with antibiotic drugs before, during, and even after the implantation of biomaterials with PRF. These systematically used drugs spread throughout the blood and lead not only to positive effects but may also induce adverse side effects on healthy tissues. Vancomycin hydrochloride (VANKA) is used to treat severe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.